文献速递肾癌与肾肿瘤

局限性肾肿物主动监测:肿瘤生长、延迟干预率及5年以上临床结局

Active Surveillance for Localized Renal Masses: Tumor Growth, Delayed Intervention Rates, and >5-yr Clinical Outcomes.
PubMed 文献 · Eur Urol · 2018-04-04

该单中心回顾性研究纳入2000至2016年457例患者共544个病灶接受主动监测(AS),中位随访67个月,5年延迟干预(DI)累积发生率为42%,5年肿瘤特异性死亡率为1.2%;初始线性生长率与DI相关但与总生存无关,DI与总生存亦无关。

要点

  • AS后DI多发生在最初2–3年,5年累积DI率为42%。
  • 初始线性生长率分组与DI相关(p=0.003),但与总生存无关(p=0.8)。
  • 5年肿瘤特异性死亡率仅1.2%,>5年未干预者99例中仅1例转移。

核心结论

  • 在严格管理的患者中,主动监测联合或不联合延迟干预是成功的策略。
  • 延迟干预多发生于最初2–3年,随时间推移需要干预的可能性降低。
  • 罕见的转移和低肿瘤特异性死亡率表明AS在中长期是安全的。

研究设计与样本

  • 单中心回顾性研究,来自前瞻性维护的肾癌数据库,2000至2016年纳入457例患者共544个病灶接受主动监测。
  • 对随访≥5年且未接受延迟干预的患者亚组进行分析。

主要发现

  • 存活患者中位随访67个月(IQR 41–94个月)。
  • 延迟干预(n=153)在1、2、3、4、5年后的累积发生率分别为9%、22%、29%、35%、42%。
  • 初始最大肿瘤中位径为2.1cm(IQR 1.5–3.1cm),初始线性生长率中位1.9mm/年(IQR 0–7),整个AS期间线性生长率中位1.9mm/年(IQR 0.3–4.2)。
  • 与无生长组相比,低初始线性生长率(HR 1.25,95%CI 0.82–1.91)、中等(HR 2.1,95%CI 1.31–3.36)、高(HR 1.87,95%CI 1.23–2.84)与延迟干预相关(p=0.003)。
  • 初始线性生长率与总生存无关(p=0.8);延迟干预与总生存无关(HR 1.34,95%CI 0.79–2.29,p=0.3);5年肿瘤特异性死亡率为1.2%(95%CI 0.4–2.8%)。

临床怎么用

  • 对于局限性肾肿物,主动监测联合或不联合延迟干预是安全的,可在严格管理下采用。
  • 延迟干预多发生在AS最初2–3年,随访中需关注此时间窗。
  • 初始线性生长率与延迟干预相关,但与总生存无关,不应单独作为干预决策依据。

局限性

  • 单中心回顾性研究,可能存在选择偏倚。
  • 亚组分析仅限随访≥5年且未延迟干预的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Active surveillance (AS) has gained acceptance as a management strategy for localized renal masses. OBJECTIVE: To review our large single-center experience with AS. DESIGN, SETTING, AND PARTICIPANTS: From 2000 to 2016, we identified 457 patients with 544 lesions managed with AS from our prospectively maintained kidney cancer database. A subset analysis was performed for patients with ≥5-yr follow-up without delayed intervention (DI). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Linear growth rates (LGRs) were estimated using linear regression for the initial LGR (iLGR) AS interval and the entire AS period. Overall survival (OS) and cumulative incidence of DI were estimated with Kaplan-Meier methods utilizing iLGR groups, adjusting for covariates. DI was evaluated for association with OS in Cox models. RESULTS AND LIMITATIONS: Median follow-up was 67 mo (interquartile range [IQR] 41-94 mo) for surviving patients. Cumulative incidence of DI (n=153) after 1, 2, 3, 4, and 5 yr was 9%, 22%, 29%, 35%, and 42%, respectively. Median initial maximum tumor dimension was 2.1cm (IQR 1.5-3.1cm). Median iLGR and overall LGR were 1.9 (IQR 0-7) and 1.9 (IQR 0.3-4.2) mm/yr, respectively. Compared with the no growth group, low iLGR (hazard ratio [HR] 1.25, 95% cumulative incidence [CI] 0.82-1.91), moderate iLGR (HR 2.1, 95% CI 1.31-3.36), and high iLGR (HR 1.87, 95% CI 1.23-2.84) were associated with DI (p=0.003). The iLGR was not associated with OS (p=0.8). DI was not associated with OS (HR 1.34, 95% CI 0.79-2.29, p=0.3). Five-year cancer-specific mortality (CSM) was 1.2% (95% CI 0.4-2.8%). Of 99 patients on AS without DI for >5 yr, one patient metastasized. CONCLUSIONS: At >5 yr, AS±DI is a successful strategy in carefully managed patients. DI often occurs in the first 2-3 yr, becoming less likely over time. Rare metastasis and low CSM rates should reassure physicians that AS is safe in the intermediate to long term. PATIENT SUMMARY: In this report, we looked at the outcomes of patients with kidney masses who elected to enroll in active surveillance rather than immediate surgery. We found that patients who need surgery are often identified early and those who remain on active surveillance become less likely to need surgery over time. We concluded that active surveillance with or without delayed surgery is a safe practice and that, when properly managed and followed, patients are unlikely to metastasize or die from kidney cancer.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. McIntosh AG, Ristau BT, Ruth K, et al. Active Surveillance for Localized Renal Masses: Tumor Growth, Delayed Intervention Rates, and >5-yr Clinical Outcomes. Eur Urol. 2018. PMID: 29625756. doi:10.1016/j.eururo.2018.03.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。